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A liquid chromatographic/mass spectrometric method to quantitate atorvastatin (AT) and its
active metabolites ortho-hydroxy (o-AT) and para-hydroxy (p-AT) atorvastatin in human, dog,
and rat plasma was validated. The method consisted of washing plasma samples at high pH
with diethyl ether and subsequently extracting the analytes and two internal standards,
[d5]-atorvastatin ([d5]-AT) and [d5]-ortho-hydroxy atorvastatin ([d5]-o-AT), from acidified
plasma by using diethyl ether. The ether layer was evaporated to dryness and the residue
reconstituted in ammonium acetate (20 mM, pH 4.0)-acetonitrile-isopropanol (60:40:1, v/v/v).
Chromatographic separation of analytes was achieved by using a YMC J’Sphere H80 (C-18)
150 3 2 mm, 4 mm particle size, column with a mobile phase consisting of acetonitrile–0.1%
acetic acid, (70:30, v/v). Analytes were detected by using MS/MS. Sample introduction and
ionization was by electrospray ionization in the positive ion mode. The method proved
suitable for routine quantitation of AT, o-AT, and p-AT over the concentration range of 0.250
to 25.0 ng/mL. Approximate retention time ranges of p-AT, o-AT, [d5]-o-AT, AT, and [d5]-AT
were 2.27 6 0.21, 3.36 6 0.23, 3.54 6 0.46, 4.12 6 0.61, and 4.65 6 0.65 min, respectively. No
peaks interfering with quantitation were observed throughout the validation processes. Mean
recoveries of AT, o-AT, and p-AT from plasma ranged 100%–107%, 70.6%–104%, and
47.6%–85.6%, respectively. Mean recoveries of the [d5]-AT and [d5]-o-AT internal standards
ranged 98.0%–99.9% and 97.3%–97.9%, respectively. Interassay precision, based on the percent
relative deviation for replicate quality controls for AT, o-AT, and p-AT, was #7.19%, 8.28%,
and 12.7%, respectively. Interassay accuracy for AT, o-AT, and p-AT was 610.6%, 5.86%, and
15.8%, respectively. AT, o-AT, and p-AT in human, dog, and rat plasma quality controls were
stable to three freeze–thaw cycles. AT, o-AT, and p-AT were stable frozen for 127, 30 and 270
days in human, dog, and rat plasma quality control samples, respectively. Human plasma
quality control samples containing AT, o-AT, and p-AT were stable for at least 4 days at
ambient room temperature and 37 °C. The lower limit of quantitation for all analytes was 0.250
ng/mL for a 1.0-mL sample aliquot. (J Am Soc Mass Spectrom 1999, 10, 55–66) © 1999
American Society for Mass Spectrometry
Atorvastatin, [(R-(R*, R*)]-2-(4-fluorophenyl)-b,d,dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenyl-amino)-carbonyl]-1H-pyrrole-1-
heptanoic acid calcium salt is a second generation
HMG-CoA reductase inhibitor recently approved for
clinical use as a cholesterol lowering agent. Atorvastatin
(AT) is a potent inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-Co A), the rate-
limiting enzyme in cholesterol biosynthesis. This syn-
thetic HMG-CoA reductase inhibitor induces a
significant reduction in total cholesterol, low-density
lipoprotein cholesterol, and plasma triglycerides in clin-
ical studies [1, 2].
Existing validated assays for AT included an enzyme
inhibition assay [3] and a gas chromatography/mass
spectrometry (GC/MS) assay [4]. The enzyme inhibi-
tion assay (EIA) was nonspecific, measuring AT and its
active metabolites based on the inhibition of HMG-CoA
reductase. The GC/MS method, although very sensi-
tive, was specific for only AT and the procedure re-
quired two derivatization steps. The pharmacokinetics
of AT’s active metabolites could only be estimated as
AT equivalents by using the difference between the EIA
and GC/MS assays [5]. Thus, there was a need to
simultaneously measure AT, and its hydroxylated me-
tabolites, for clinical and preclinical studies. The quan-
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titation of drugs in biological matrices by LC/MS/MS
been previously reported [6–8]. HPLC/MS/MS has
been used for the analysis of statins and their metabo-
lites, such as lovastatin [9], simvastatin [10], and dalv-
astatin [11] and other hypolipidemics such as SQ-33600
[12]. This report describes a sensitive and specific liquid
chromatography (LC)/MS/MS method for the simulta-
neous quantitation of AT and its active metabolites,
ortho-hydroxy atorvastatin (o-AT) and para-hydroxy
atorvastatin (p-AT).
The structures of AT, o-AT, and p-AT are shown in
Figures 1, 2, and 3, respectively. The deuteriums in the
[d5]-AT and [d5]-o-AT analogs are located on the phe-
nyl rings labeled with an asterisk on the respective
structures in Figures 1 and 2.
Experimental
Materials and Chemicals
AT, o-AT, p-AT, [d5]-o-AT, and [d5]-AT were supplied
by Parke-Davis Pharmaceutical Research Division of
Warner-Lambert (Ann Arbor, MI). Acetonitrile, water,
sodium hydroxide (6.7 N concentrate), diethyl ether,
85% phosphoric acid, isopropanol, and ammonium
acetate were obtained from Mallinckrodt Baker (Paris,
KY). Acetic acid was supplied by EM Sciences (Gibbs-
town, NJ). N,N-dimethylacetamide (991%) was pur-
chased from Aldrich Chemical (Milwaukee, WI). Hep-
arinized human plasma was supplied by Interstate
Blood Bank (Memphis, TN). Heparinized dog and rat
plasmas were purchased from Pel-Freeze Biologicals
(Rogers, AR). All mobile phase solvents were HPLC
Grade and all reagents were Analytical Reagent Grade.
Liquid Chromatography-Tandem Mass
Spectrometry
The liquid chromatographic system consisted of a Se-
ries 200 LC pump and autosampler from Perkin-Elmer
(Norwalk, CT). The detector was a Micromass
(Manchester, UK) Quattro II Mass Spectrometer. The
HPLC column was a YMC (Willmington, NC) J’Sphere
H80 (C-18), 150 3 2 mm, 4 mm particle size. The mobile
phase consisted of acetonitrile: 0.1% acetic acid (70:30,
v/v) and was delivered at a flow rate of 0.2 mL/min.
The sample injection volume was 40 mL. The mass
spectrometer was operated in the multiple reaction
monitoring (MRM) mode. Sample introduction and
ionization was electrospray ionization in the positive
ion mode. The cone voltage was 20 V and the source
temperature was 140 °C. Ions were collisionally acti-
vated at a collision energy of 35 eV and at an indicated
argon pressure of 2.0 3 1023 torr. To assay all analytes,
the mass spectrometer was operated at unit mass reso-
lution and set to select the [M1H]1 ions of m/z 559.3
for AT, 575.3 for o-AT and p-AT, 564.3 for [d5]-AT, and
580.3 for [d5]-o-AT via the first quadrupole. Signals for
product ions of m/z 440.2 and 445.2 for analytes and
internal standards, respectively, were monitored via the
third quadrupole mass filter. The dwell time for each
transition was 100 ms and the interchannel delay was 20
ms. MRM data were acquired and integrated by using
the MassLynx software package (version 2.22).
Preparation of Standard Solutions
Fresh stock solutions were prepared for each batch run
beginning with the weighing of compounds. Stock
solution I, 1.0 mg/mL, was prepared by dissolving 5 to
22 mg of analyte in 1.0-mL dimethylacetamide. Solu-
tions were permitted to stand at room temperature for
at least 30 min to complete dissolution. The volume of
each solution was adjusted with acetonitrile–water (50:
50, v/v) to produce a 1.0-mg/mL stock solution for
Figure 2. Structure of ortho-hydroxy atorvastatin. The [d5] ana-
log incorporates the isotopic label on the ring indicated with an
asterisk. The masses of the fragment ions are shown and refer to
the unlabeled analog.
Figure 3. Structure of para-hydroxy atorvastatin. The masses of
the fragment ions are shown.
Figure 1. Structure of atorvastatin. The [d5] analog incorporates
the isotopic label on the ring indicated with an asterisk. The
masses of the fragment ions are shown and refer to the unlabeled
analog.
56 BULLEN ET AL. J Am Soc Mass Spectrom 1999, 10, 55–66
each analyte. Stock solution II, containing 25 mg/mL
each of AT, o-AT, and p-AT was prepared by combin-
ing aliquots of each analyte’s stock solution I and
diluting with water. Stock solution III, 2500 ng/mL in
water and a working standard, 1000 ng/mL in plasma,
were prepared by serial dilution of stock solution II.
Plasma calibration standards were prepared by serial
dilution of the 1000-ng/mL working standard.
Stock solution IV, containing 10 mg/mL of the deu-
terated internal standards, was prepared by diluting the
appropriate stock solution I with water. A working
standard, 25 ng/mL, was prepared by serial dilution of
stock solution IV with plasma. Addition of 200-mL
aliquots of the working solution to samples gave a
concentration of 5.0 ng/mL of each deuterated IS.
Plasma quality controls (QCs) at three concentrations
of AT, o-AT, and p-AT were prepared by serial dilu-
tions of stock solution II. These QCs were subdivided
into 2.5-mL aliquots and were stored frozen in 2 dram
glass vials. Lower limit of quantitation samples (LLOQ)
containing a nominal concentration of 0.250 ng/mL of
AT, o-AT, and p-AT were prepared and stored in a
similar fashion. QCs and LLOQs were prepared by
weighings of analytes that were independent of those
used for calibration standards.
Extraction Procedure
Samples, QCs, and LLOQs, were thawed at 37 °C,
thoroughly mixed, and centrifuged at 2600 3 g for 10
min prior to the sampling step. Plasma, 1.0 mL, 0.2 mL
internal standard, 0.5 mL 1.0 N NaOH, in that order,
were added to a 16 3 125-mm screw cap culture tube
and vortexed for 60 s on a multitube vortexer. Diethyl
ether, 5 mL, was added to each tube. The tubes were
capped and shaken horizontally for 15 min. The solu-
tions were clarified by centrifugation for 10 min at
2600 3 g. The bottom aqueous layer was frozen in an
isopropanol/dry ice bath for 10 min and the top organic
layer was discarded. The aqueous layer was thawed at
37 °C for 5 min. A 2.0-mL aliquot of 1.0 N H3PO4 was
added to each tube and the samples were vortexed as
before. Diethyl ether, 10 mL, was added to each sample
tube, tubes were capped, shaken, and centrifuged. The
bottom aqueous layer was frozen and the ether layer
was decanted into a clean 15-mL conical glass tube. The
ether was evaporated to dryness under a steady stream
of N2 in a water bath at 40 °C. The resulting residue was
reconstituted in 0.2 mL of ammonium acetate (20 mM,
pH 4.0):acetonitrile:isopropanol (60:40:1), vortexed for
60 s, and centrifuged 10 min at 2600 3 g. The super-
natants were placed in 0.2-mL glass injection vials and
sealed with polypropylene press on caps.
Data Acquisition and Analysis
The method was validated over the concentration range
of 0.250 to 25.0 ng/mL by assaying eight calibration
standards in singlet, each containing the three analytes
of interest, and three quality control samples in quadru-
plicate in three separate batch runs. The best-fit line was
determined by least-squares linear regression of the
calibration data from each batch run using a weighting
factor of 1/concentration2 [13]. For all plasma species,
[d5]-AT was used as the internal standard for AT. For
the human and rat plasma assays, [d5]-o-AT was used
as the internal standard for both hydroxy metabolites.
For the dog plasma assay, [d5]-AT was used for both
hydroxy metabolites because of the unavailability of
[d5]-o-AT at the time of assay validation. MRM re-
sponses were smoothed twice, prior to integration,
using a mean smoothing algorithm with window sizes
of 8 to 11 points. Concentrations of analytes were
determined using peak-area ratios and the regression
parameters. Peak areas, regression parameters, and
concentrations were obtained by using the quantify
portion of MassLynx.
Results and Discussion
The goal of this work was to develop and validate a
robust, sensitive, and selective assay for the simulta-
neous extraction and quantitation of AT, o-AT, and
p-AT, suitable for determining the pharmacokinetics of
these compounds in clinical and preclinical studies. The
previously mentioned GC/MS method was not suitable
for the hydroxylated metabolites that did not survive
the derivatization steps. A solid phase extraction (SPE)
method utilizing cyclohexane cartridges showed early
promise but recoveries of the analytes lacked sufficient
reproducibility. A liquid/liquid extraction protocol that
incorporated a back extraction step proved to be the
most robust technique and provided the cleanest sam-
ples. In retrospect, the back extraction may have pro-
vided an added benefit by minimizing ion suppression
similar to that reported by Buhrman [14] as well as
providing much cleaner samples. Internal standard(s)
dissolved in plasma rather than water offered an ad-
vantage for the reproducibility of the peak area of the
internal standards. The recovery from the final recon-
stitution step was optimized by the addition of ammo-
nium acetate buffer (pH 4.0). Addition of 1% isopropa-
nol to the reconstitution solvent minimized binding to
glass and carryover in the sample injector. The authors
have injected as many as 150 samples in a single batch
run without any apparent affects on sensitivity or
precision. A contract lab has been able to validate the
human assay suggesting the assay is rugged as well as
transferable.
Assay Selectivity
Utilizing decomposition transitions for each compound
enhanced mass spectrometric selectivity. Because the
analytes have a carboxylic acid moiety, electrospray in
negative ion mode was evaluated but was less sensitive
than the positive ion mode. Likewise, APCI was also
assessed but provided no advantages over electrospray.
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Product ion mass spectra of authentic standards of AT
[M1H]1 of m/z 559.3, and [d5]-AT [M1H]
1 of m/z
564.3 are shown in Figure 4. o-AT [M1H]1 of m/z
575.3, p-AT [M1H]1 of m/z 575.3, and [d5]-o-AT
[M1H]1 m/z of 580.3 are shown in Figure 5. The
predominant product ion of m/z 440.2 is specific for
AT and its hydroxylated metabolites. The predominant
product ion of m/z 445.2 is specific for the correspond-
ing deuterated analogs. The fragmentation schemes for
these analytes are marked on the structures in Figures 1,
2, and 3. The collision induced decomposition transi-
tions of 559.3 3 440.2 (AT), 564.3 3 445.2 ([d5]-AT),
580.3 3 445.2 ([d5]-o-AT), 575.3 3 440.2 (p-AT), and
575.33 440.2 (o-AT) were chosen for multiple reaction
monitoring (MRM) of the analytes in the LC separation.
Chromatographic selectivity of the method was
demonstrated by the absence of interfering peaks ob-
served at the retention times for AT, o-AT, p-AT, and
[d5]-AT and [d5]-o-AT from blank plasma samples from
at least eight independent sources for each species.
Interferences from endogenous materials were mini-
mized by the combination of sample preparation,
HPLC, and MS/MS. MRM ion chromatograms of ex-
tracted blank plasma samples from human, dog, and rat
without either analytes or internal standards present
are shown in Figures 6, 7, and 8, respectively. Assay
selectivity was confirmed by the absence of interfering
peaks at the retention times of the five analytes of
interest (see Figures 6, 7, and 8). Separate MRM ion
chromatograms were constructed for each injection. In
each set of chromatograms the traces represent the
relative abundance of ions corresponding to the transi-
tions described earlier. Dog plasma extracts do not
contain [d5]-o-AT because it was unavailable at the time
of the assay validation.
Fragments, such as m/z 466.2, were not unique.
Thus the use of the more intense identical transition,
m/z 575.33 440.2, for o-AT and p-AT with chromato-
graphic resolution of the analytes provided the desired
assay sensitivity. Extracted 1.0 ng/mL calibration stan-
dards for human, dog, and rat plasmas are shown in
Figures 9, 10, and 11, respectively. These examples
indicate there is adequate chromatographic resolution
of o-AT and p-AT. Chromatographic resolution of o-AT
and p-AT was routinely assessed prior to initiation of
an analysis by test injections of extracted calibration
standards. If resolution was unsatisfactory, the percent
organic in the mobile phase composition was adjusted.
All three assay validations as well as all sample analy-
ses were performed on the same YMC column, repre-
senting more than 1000 injections.
Linearity
The peak area ratios of calibration standards were
proportional to the concentration of analytes in each
assay over the nominal concentration range of 0.250 to
25.0 ng/mL. The calibration curves appeared linear and
were well described by least-squares regression lines. A
weighting factor of 1/concentration2 was chosen to
Figure 4. Electrospray product ion mass spectra of the precursor ions of atorvastatin ([M1H]1 m/z
of 559.3 (A), and of [d5]-atorvastatin ([M1H]
1 m/z of 564.3 (B).
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achieve homogeneity of variance. The slopes, inter-
cepts, and coefficient of determinations from the vali-
dation analyses appear in Table 1.
Accuracy and Precision
Interrun (between-run) precision and accuracy were
determined by pooling all individual assay results of
quadruplicate quality controls over the three separate
batch runs. Interrun precision and accuracy of the
calibration standards was assessed in a similar fashion
using the three calibration curves used for assay vali-
dation. Intrarun (within run) precision and accuracy
were determined by assaying quality controls in qua-
druplicate at each of three levels, in three separate batch
runs.
Accuracy is defined as the percent relative error
(%RE) and was calculated using the following formula
%RE 5 (E 2 T)(100/T) where E is the experimentally
determined concentration and T is the theoretical con-
centration. Assay precision was calculated by using the
following formula %RSD 5 (SD/M)(100) where M is
the mean of the experimentally determined concentra-
tions and SD is the standard deviation of M.
Tables 2, 3, and 4 summarize the interrun accuracy and
precision for the AT, o-AT, and p-AT, plasma calibration
standards, respectively. The interrun precision was
,6.30%, 10.5%, and 17.4% for AT, o-AT and p-AT, respec-
tively. The interrun accuracy was 6 4.73%, 8.47%, and
7.42% for AT, o-AT and p-AT, respectively.
Tables 5, 6, and 7 summarize the intrarun accuracy
and precision for AT, o-AT and p-AT, plasma quality
Figure 5. Electrospray product ion mass spectra of the precursor ions of ortho-hydroxy atorvastatin
([M1H]1 m/z of 575.3 (A), and of para-hydroxy atorvastatin ([M1H]1 m/z of 575.3 (B), and
[d5]-ortho-hydroxy atorvastatin ([M1H]
1 m/z of 580.3 (C).
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control samples, respectively. The intrarun precision
was ,4.43%, 8.60%, and 16.7% for AT, o-AT and p-AT,
respectively. The intrarun accuracy was g 13.4%, 12.2%,
and 20.3% for AT, o-AT and p-AT, respectively.
Figure 9. MRM ion chromatograms of an extracted 0.250 ng/ml
human plasma calibration standard of atorvastatin, ortho-hydroxy
atorvastatin, and para-hydroxy atorvastatin. Letters indicate ap-
proximate retention times of (A) [d5]-ortho-hydroxy atorvastatin,
(B) para-hydroxy atorvastatin, (C) ortho-hydroxy atorvastatin, (D)
[d5]-atorvastatin, and (E) atorvastatin.
Figure 6. MRM ion chromatograms of blank extracted human
plasma sample without analytes or internal standard. Letters
mark approximate retention times of analytes of interest: (A)
[d5]-ortho-hydroxy atorvastatin, (B) para-hydroxy atorvastatin,
(C) ortho-hydroxy atorvastatin, (D) [d5]-atorvastatin, and (E)
atorvastatin. Responses normalized to lowest response in LLOQ
sample (Figure 9).
Figure 7. MRM ion chromatograms of an extracted control dog
plasma without analytes or internal standard. Letters indicate
approximate retention times of (B) para-hydroxy atorvastatin, (C)
ortho-hydroxy atorvastatin, (D) [d5]-atorvastatin, and (E) atorva-
statin.
Figure 8. MRM ion chromatograms of blank extracted rat
plasma sample without analytes or internal standard. Letters
mark approximate retention times of analytes of interest, (A)
[d5]-atorvastatin, (B) para-hydroxy atorvastatin, (C) ortho-hy-
droxy atorvastatin, (D) [d5]-atorvastatin, and (E) atorvastatin. Re-
sponses normalized to lowest response in LLOQ sample (Figure 11).
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Table 8 summarizes the interrun accuracy and pre-
cision for AT, o-AT and p-AT, plasma quality control
samples. The interrun precision was ,7.19%, 8.28%,
and 11.8% for AT, o-AT and p-AT, respectively. The
interrun accuracy was 6 10.6%, 5.86%, and 11.9% for
AT, o-AT and p-AT, respectively.
Lower Limit of Quantitation
The lower limit of quantitation is defined as the lowest
concentration of the calibration standards yielding ac-
curacy and precision of 620%. These data are tabulated
in Table 8 for AT, o-AT and p-AT. The precision of the
LLOQ plasma samples containing AT, o-AT and p-AT
is 11.3%, 12.8%, and 12.7%, respectively. The accuracy
of the LLOQ plasma samples containing AT, o-AT, and
p-AT is 13.6%, 5.69%, and 15.8%, respectively.
Recovery
The extraction efficiencies of AT, o-AT, p-AT, [d5]-AT,
and [d5]-o-AT from human, dog, and rat plasma, ex-
pressed as mean percent recovered, were determined
by analysis of nine samples at each of three quality
control concentrations for the analytes of interest and at
one concentration for the internal standards. Percent
recovery was determined by comparing the peak area
ratios of extracted analytes to the peak area ratios of
nonextracted standards. Mean recoveries and %RSD for
each analyte are summarized in Table 9. The recovery of
[d5]-o-AT from dog plasma extracts was not assessed
because the compound was unavailable at the time of
assay validation. The data suggest the recoveries of AT,
o-AT, and p-AT were concentration independent in the
tested ranges from human, dog, and rat plasmas.
System Repeatability
The system repeatability, given as percent relative stan-
dard deviation (%RSD) of mean peak-area ratios, was
assessed using at least nine replicate injections of
pooled extracted samples at the three quality control
concentrations for the analytes and at 5.0 ng/mL for the
internal standards. System repeatability is shown in
Table 10 for all compounds and species.
Stability
The stability of the analytes was assessed in stock
solution I, injection solvent, biological matrix, and to
three freeze–thaw cycles. Analytes were considered
stable if the deviation of the mean test responses were
within 15% of appropriate controls. Analytes were
tested using the quality control samples whenever
appropriate. The peak area ratios of the AT, o-AT, and
p-AT stock solution I were within 15% of freshly
prepared stock solution I after 35 days at ambient room
temperature. The peak area ratios of AT, o-AT, p-AT,
and [d5]-AT stock solution I, refrigerated for 190 days
were within 10% of freshly prepared stock solution I.
The response of [d5]-o-AT stock solution I, refrigerated
for 121 days was within 11% of freshly prepared stock
Figure 10. MRM ion chromatogram of an extracted 1.00 ng/ml
dog plasma calibration standard of atorvastatin, ortho-hydroxy ator-
vastatin, and para-hydroxy atorvastatin. Letters indicate approxi-
mate retention times of (B) para-hydroxy atorvastatin, (C) ortho-
hydroxy atorvastatin, (D) [d5]-atorvastatin, and (E) atorvastatin.
Figure 11. MRM ion chromatograms of an extracted 0.250 ng/ml
rat plasma calibration standard of atorvastatin, ortho-hydroxy
atorvastatin, and para-hydroxy atorvastatin. Letters indicate ap-
proximate retention times of (A) [d5]-ortho-hydroxy atorvastatin,
(B) para-hydroxy atorvastatin, (C) ortho-hydroxy atorvastatin, (D)
[d5]-atorvastatin, and (E) atorvastatin.
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Table 2. Interrun accuracy and precision of atorvastatin human, dog and rat plasma calibration standards
Standard
(ng/mL)
Human plasma (N 5 3) Dog plasma (N 5 3) Rat plasma (N 5 3)
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
0.243 0.240 1.29 21.23 0.242 2.89 20.41 0.244 2.87 0.41
0.487 0.496 3.93 1.85 0.487 4.70 0 0.494 6.30 1.44
0.973 0.980 2.44 0.72 0.948 2.26 22.60 0.927 0.50 24.73
2.43 2.43 1.66 0 2.49 3.00 2.61 2.44 2.26 0.41
4.87 4.85 1.40 20.41 4.84 1.26 20.62 4.94 1.30 1.44
9.73 9.82 1.35 0.92 9.86 1.19 1.34 9.73 1.03 20.31
19.5 19.2 0.301 21.54 19.7 2.30 0.85 19.4 1.55 20.51
24.3 24.2 1.86 20.41 24.0 0.24 21.37 24.7 1.24 1.65
Table 3. Interrun accuracy and precision of ortho-hydroxy atorvastatin human, dog, and rat plasma calibration standards
Standard
(ng/mL)
Human plasma (N 5 3) Dog plasma (N 5 3) Rat plasma (N 5 3)
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
0.236 0.226 2.52 24.24 0.239 8.03 1.27 0.231 2.81 22.12
0.471 0.502 4.08 6.58 0.474 10.0 0.64 0.483 5.18 2.55
0.942 0.965 1.40 2.44 0.894 8.34 25.13 0.956 2.87 1.49
2.36 2.37 2.68 0.42 2.56 10.5 8.47 2.43 1.71 2.97
4.71 4.63 2.08 21.70 4.62 4.83 21.91 4.73 1.67 0.42
9.42 9.30 2.15 21.27 9.80 3.39 4.39 9.14 2.08 22.97
18.8 18.7 0.61 20.53 18.2 5.20 23.37 18.5 2.05 21.60
23.6 23.4 3.70 20.85 22.4 2.57 24.94 23.4 1.73 20.85
Table 4. Interrun accuracy and precision of para-hydroxy atorvastatin human, dog, and rat plasma calibration standards
Standard
(ng/mL)
Human plasma (N 5 3) Dog plasma (N 5 3) Rat plasma (N 5 3)
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
0.238 0.236 2.88 20.84 0.238 4.20 0 0.240 3.38 0.84
0.476 0.450 17.4 25.46 0.496 10.4 4.27 0.468 8.95 21.68
0.952 0.975 12.4 2.42 0.948 8.62 20.42 0.934 4.31 21.89
2.38 2.37 4.64 20.42 2.25 13.2 25.60 2.45 8.49 2.94
4.76 4.67 3.21 21.89 4.78 8.58 0.42 4.83 4.87 1.47
9.52 8.92 10.1 26.30 10.1 5.18 6.41 9.75 2.86 2.42
19.0 19.5 2.63 2.63 19.5 10.4 2.81 18.5 3.55 22.63
23.8 24.4 9.18 2.52 22.0 7.72 27.42 23.4 3.34 21.68
Table 1. Slopes, intercepts, and coefficients of determination of atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy
atorvastatin human, dog, and rat plasma calibration curves used for assay validation
Specie
Atorvastatin Ortho-hydroxy atorvastatin Para-hydroxy atorvastatin
Slope Intercept
Coefficient of
determination Slope Intercept
Coefficient of
determination Slope Intercept
Coefficient of
determination
Human 1.16 20.00279 0.9980 1.30 0.0489 0.9933 0.893 0.00416 0.9792
1.20 0.00316 0.9997 1.33 20.00753 0.9990 0.983 20.00803 0.9917
1.21 20.00182 0.9991 1.36 0.00472 0.9990 1.03 20.00236 0.9925
Dog 1.08 0.000710 0.9998 0.519 20.00265 0.9994 0.325 0.00299 0.9914
1.09 20.0149 0.9990 0.585 0.00598 0.9887 0.480 20.00369 0.9981
1.03 0.00722 0.9996 0.485 0.00267 0.9961 0.289 0.00269 0.9651
Rat 1.24 0.00402 0.9999 1.32 20.0413 0.9991 1.33 20.0430 0.9985
1.18 20.00350 0.9998 1.35 20.0359 0.9998 1.23 0.0144 0.9968
1.23 20.00970 0.9989 1.38 20.110 0.9984 1.30 0.00286 0.9977
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solution I. These data indicate the five analytes are
stable in stock solution I under the conditions tested.
The chromatographic responses of all five extracted
analytes in injection solvent after 7, 22, and 16 h at
ambient temperature (approximately 20 °C) were
within 15% of initial values for human, dog, and rat
plasma extracts, respectively, indicating sufficient sta-
bility in the injection solvent for the period of time of a
typical analytical run.
The mean concentrations of AT, o-AT, and p-AT in
human, dog, and rat plasma quality controls stored
frozen for 127, 30, and 270 days, respectively, were
within 15% of control values. The mean concentrations
of AT, o-AT, and p-AT in human plasma quality
controls were within 10% of control values after 4 days
at ;22 and ;37 °C.
After three freeze–thaw cycles, the mean concentra-
tions of the quality controls were within 4.8%, 11.6%,
Table 6. Intrarun accuracy and precision (N 5 4) for the determination of ortho-hydroxy atorvastatin in human, dog, and rat
plasma by LC/MS/MS
Species Batch
Low quality control
0.584 ng/mL
Mid quality control
4.38 ng/mL
High quality control
17.5 ng/mL
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Human 1 0.533 0.94 25.66 4.24 3.75 0 18.4 1.74 8.24
2 0.607 0.97 7.43 4.34 1.98 2.36 17.0 1.88 0
3 0.576 3.33 1.95 4.22 2.16 20.47 17.1 0.76 0.59
Dog 1 0.559 5.83 21.15 4.14 6.38 22.36 17.8 4.02 4.41
2 0.509 8.60 29.91 3.77 3.53 211.0 14.9 4.90 212.2
3 0.528 3.46 26.50 4.09 2.09 23.48 16.2 3.53 24.71
Rat 1 0.567 3.83 0.35 4.25 6.94 0.24 17.5 5.43 2.94
2 0.544 2.85 23.72 4.21 2.35 20.71 18.0 4.78 5.88
3 0.578 2.16 2.30 4.02 4.05 25.19 16.0 3.94 25.88
Table 7. Intrarun accuracy and precision (N 5 4) for the determination of para-hydroxy atorvastatin in human, dog, and rat plasma
by LC/MS/MS
Species Batch
Low quality control
0.571 ng/mL
Mid quality control
4.28 ng/mL
High quality control
17.1 ng/mL
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Human 1 0.585 6.74 2.45 4.28 6.78 0 16.5 16.2 23.51
2 0.645 13.7 13.0 4.30 13.2 0.47 17.5 10.6 2.34
3 0.687 9.87 20.3 4.25 14.4 20.70 17.5 3.54 2.34
Dog 1 0.563 15.2 21.36 4.13 7.43 23.56 17.5 7.96 2.05
2 0.568 7.04 20.52 4.31 4.88 0.76 16.5 5.29 23.80
3 0.613 10.6 7.27 4.56 9.37 6.60 17.8 12.1 3.80
Rat 1 0.574 3.22 0.53 4.14 5.24 23.27 16.1 5.67 25.85
2 0.609 7.04 6.65 4.59 4.20 7.24 17.2 16.7 0.58
3 0.607 8.32 6.30 3.98 4.87 27.01 17.9 8.49 4.68
Table 5. Intrarun accuracy and precision (N 5 4) for the determination of atorvastatin in human, dog, and rat plasma by
LC/MS/MS
Species Batch
Low quality control
0.584 ng/mL
Mid quality control
4.38 ng/mL
High quality control
17.5 ng/mL
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Mean
(ng/mL) %RSD %RE
Human 1 0.584 2.84 0 4.38 1.12 0 18.2 2.14 4.00
2 0.506 4.43 213.4 4.10 2.63 26.39 16.3 3.93 26.86
3 0.531 4.29 29.08 3.98 1.37 29.13 16.2 0.78 27.43
Dog 1 0.548 1.99 26.21 4.16 1.50 25.08 16.7 0.75 24.43
2 0.558 2.65 24.41 4.22 2.60 23.60 16.6 1.24 25.29
3 0.528 0.87 29.63 4.20 1.52 24.17 16.9 3.37 23.57
Rat 1 0.514 2.65 212.0 4.06 1.80 27.31 17.6 4.15 0.57
2 0.537 4.00 28.05 4.31 1.67 21.60 18.2 2.64 4.00
3 0.516 2.13 211.6 3.93 2.21 210.3 16.1 3.04 28.00
63J Am Soc Mass Spectrom 1999, 10, 55–66 LC/MS/MS ASSAY OF ATORVASTATIN AND ACTIVE METABOLITES
and 7.29% of the appropriate human, dog, and rat
plasma controls, respectively. These data indicate the
analytes are stable for up to three freeze–thaw cycles
under the conditions tested.
Applicability of Method
The method was utilized for determining the plasma
concentrations of AT, o-AT, and p-AT for pharmacoki-
Table 8. Interrun accuracy and precision for the determination of atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy
atorvastatin in human, dog, and rat plasma by LC/MS/MS
Concentration
(ng/mL)
Atorvastatin
LLOQ quality control
0.243
Atorvastatin
low quality control
0.584
Atorvastatin
mid quality control
4.38
Atorvastatin
high quality control
17.5
Species N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE
Human 12 0.210 11.3 213.6 12 0.540 7.19 27.53 12 4.15 4.53 25.25 12 16.9 6.21 23.37
Dog 12 0.238 4.24 22.19 12 0.545 3.03 26.75 12 4.19 1.89 24.34 12 16.7 2.10 24.57
Rat 8 0.233 7.81 24.12 12 0.522 3.43 210.6 12 4.10 4.41 26.39 12 17.3 6.13 21.14
Concentration
(ng/mL)
Ortho-hydroxy atorvastatin
LLOQ quality control
0.236
Ortho-hydroxy atorvastatin
low quality control
0.565
Ortho-hydroxy
atorvastatin
mid quality control
4.24
Ortho-hydroxy
atorvastatin
high quality control
17.0
Species N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE
Human 12 0.233 12.8 21.27 12 0.572 5.82 1.24 12 4.27 2.79 0.71 12 17.5 4.17 2.94
Dog 12 0.249 12.1 5.69 12 0.532 6.92 25.86 12 4.00 5.85 25.66 12 16.3 8.28 24.12
Rat 8 0.244 7.62 3.39 12 0.563 3.80 20.35 12 4.16 5.05 21.89 12 17.2 6.74 1.18
Concentration
(ng/mL)
Para-hydroxy atorvastatin
LLOQ quality control
0.238
Para-hydroxy atorvastatin
low quality control
0.571
Para-hydroxy atorvastatin
mid quality control
4.28
Para-hydroxy atorvastatin
high quality control
17.1
Species N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE N
Mean
(ng/mL) %RSD %RE
Human 12 0.233 12.7 22.10 12 0.639 11.8 11.9 12 4.28 10.8 0 12 17.2 10.5 0.58
Dog 12 0.276 11.9 15.8 12 0.574 11.2 0.541 12 4.33 8.07 1.27 12 17.2 8.84 0.682
Rat 8 0.252 10.8 5.88 12 0.597 6.63 4.55 12 4.24 7.62 20.93 12 17.0 11.3 20.58
Table 9. Percent recovery (%RSD) of atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, [d5]-atorvastatin, and [d5]-
ortho-hydroxy atorvastatin from human, dog, and rat plasma
Concentration
(ng/mL)
Atorvastatin [d5]-Atorvastatin
5.00.584 4.38 17.5
Human 101 (6.60) 102 (1.34) 102 (0.93) 98.4 (3.55)
Dog 103 (4.62) 100 (2.84) 101 (4.20) 98.9 (3.89)
Rat 107 (3.90) 102 (1.68) 102 (1.71) 98.0 (1.68)
Concentration
(ng/mL)
Ortho-hydroxy atorvastatin [d5]-Ortho-hydroxy
atorvastatin
5.00.565 4.24 17.0
Human 104 (4.34) 102 (2.33) 101 (2.10) 97.9 (3.18)
Dog 72.2 (8.41) 70.6 (3.79) 73.0 (5.56) n/aa
Rat 101 (5.92) 103 (2.52) 103 (2.64) 97.3 (2.52)
Concentration
(ng/mL)
Para-hydroxy atorvastatin
0.571 4.28 17.1
Human 63.6 (7.55) 64.8 (6.19) 71.6 (6.01)
Dog 47.6 (7.41) 47.9 (4.64) 51.3 (7.37)
Rat 77.9 (7.83) 79.9 (6.91) 85.6 (4.88)
a n/a 5 not assessed, dog plasma assay did not utilize [d5]-ortho-hydroxy atorvastatin.
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netic analysis in a t-tube biliary excretion study in
humans [15] following a single oral dose of 40 mg of
[14C]-AT (50 mCi). Blood samples were collected in
heparinized tubes before, and at 1, 2, 3, 4, 6, 8, 12, 24, 36,
48, 72, and 120 h following drug administration. Plasma
was harvested by centrifugation and stored frozen until
analysis. Figure 12 is an MRM ion chromatogram of an
extracted plasma sample from a human subject 4 h after
administration of the AT oral dose. The analyte concen-
trations in this sample were 5.0, 3.37, 46.0, 5.0, and 27.9
ng/mL for [d5]-o-AT, p-AT, o-AT, [d5]-AT, and AT,
respectively. Figure 13 is a plasma concentration vs.
time curve from one subject in the study indicating
successful application of the method. The method was
also successfully applied to toxicokinetic studies in rat
and dog. The results of these studies will be published
elsewhere.
Conclusion
A liquid chromatographic mass spectrometric method
to quantitate AT, o-AT, and p-AT in human, dog, and
rat plasma has been validated. The method is sensitive
and selective as well as suitable for determining the
pharmacokinetics of these compounds in clinical and
preclinical studies. The nominal lower limit of quanti-
tation for all analytes was 0.250 ng/mL for a 1.0-mL
sample aliquot. The method is suitable for routine
quantitation samples AT, o-AT, and p-AT at nominal
Figure 12. MRM ion chromatograms of an extracted plasma sample from a human subject 4 h after
administration of a single oral dose of 40 mg of [14C]-atorvastatin (50 mCi). Concentrations of (A)
[d5]-ortho-hydroxy atorvastatin, (B) para-hydroxy atorvastatin, (C) ortho-hydroxy atorvastatin, (D)
[d5]-atorvastatin, and (E) atorvastatin are 5.0, 3.37, 46.0, 5.0, and 27.9 ng/mL, respectively.
Table 10. System repeatability, percent relative standard
deviation (%RSD) of mean peak-area ratios of atorvastatin,
ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, [d5]-
atorvastatin, and [d5]-ortho-hydroxy atorvastatin from human,
dog, and rat plasma extracts of pooled quality control samples
Concentration
(ng/mL)
Atorvastatin
[d5]-Atorvastatin
5.00.584 4.38 17.5
Human 3.02 1.38 0.91 3.21
Dog 3.26 1.48 1.61 4.24
Rat 1.98 1.78 2.26 8.35
Concentration
(ng/mL)
Ortho-hydroxy
atorvastatin
[d5]-Ortho-hydroxy
atorvastatin
5.00.565 4.24 17.0
Human 3.33 1.31 1.31 3.06
Dog 2.58 1.82 2.13 n/aa
Rat 2.86 1.78 1.69 9.06
Concentration
(ng/mL)
Para-hydroxy
atorvastatin
0.571 4.28 17.1
Human 5.13 2.69 2.51
Dog 4.84 3.48 3.77
Rat 10.6 5.84 5.30
a n/a 5 not assessed, dog plasma assay did not utilize [d5]-ortho-
hydroxy atorvastatin.
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concentrations in human, dog, and rat plasma from
0.250 to 25.0 ng/mL.
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